BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology milestones include seven ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology ...

Ugur Sahin, M.D., Co-Founder and CEO of BioNTech, is a physician, immunologist and leader in the development of novel ...

The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

File Photo: Syringes are seen in front of displayed Biontech and Pfizer logos in this illustration taken November 10, 2020 (Reuters) BioNTech co-founder Ugur Sahin on Thursday said the frontrunner ...

With the merger's completion on January 6, 2026, CureVac's era on the public markets will end. The focus will shift entirely to integrating its clinical candidates, particularly in cancer ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which ...

Gazeteci Fatih Ergin'in gündeme taşıdığı iddialara göre, Pfizer'in avukatları Türkiye'ye hiç BioNTech aşısı satılmadığını öne sürdü ve yurttaşlara uygulanan aşıların kaynağının belirsiz olabileceğini ...